# US 2021/0199659 A1 · Thymidine kinase (tk-1) in prognostic indices for dlbcl

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0199659 A1
- Document ID: US20210199659A1
- Status: Published application
- Kind: A1
- Application number: 17/186,163
- Filed: 2021-02-26
- Published: 2021-07-01
- Earliest claimed: 2018-08-31
- Assignees: Roche Diagnostics Operations, Inc.
- Applicants: Roche Diagnostics Operations, Inc.
- Inventors: Vinzent Rolny; Sandra Rutz; David Morgenstern; Boris Pinchuk; Christina Zimmermann; Martin Klammer; Franziska Sonner
- Web page: https://patentgrep.com/patent/US20210199659A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C12Q 1/485: {involving kinase}
- G01N 33/48: Biological material, e.g. blood, urine (G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence); Haemocytometers (counting blood corpuscules distributed over a surface by scanning the surface G06M11/02)
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/552: Glass or silica
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 2333/9122: Thymidine kinase (2.7.1.21)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

## Claims

### Claim 1

A method of determining a prognostic index (PI) (also called risk score or PI-score) for a diffuse large B-cell lymphoma (DLBCL) patient the method comprising
a) determining at least the following parameters:
i) extranodal disease status; ii) Ann Arbor stage; and iii) the level of thymidine kinase 1,
wherein absence of extranodal disease values 0 points and presence of extranodal disease values 1 point,
wherein an Ann Arbor stage of I or II values 0 points and an Ann Arbor stage of III or IV values 1 point, and
wherein a level of the thymidine kinase up to and including the cut-off values 0 points and wherein a level of the thymidine kinase above cut-off values at least 1 point, and
b) summing up the values for i), ii) and iii) in the determination of the PI.

### Claim 2 (depends on 1)

The method of claim 1, wherein the thymidine kinase cut-off level is set to 4 times the mean value of the TK-1 level as determined in healthy individuals, wherein a thymidine kinase level up to and including the cut-off values 0 points and wherein any TK-1 level above cut-off values 1 point.

### Claim 3 (depends on 1)

The method of claim 1, wherein the thymidine kinase cut-off level is set to 4 times the mean value of the TK-1 level as determined in healthy individuals, wherein a low thymidine kinase level, i.e. a level of TK-1 up to and including the cut-off values 0 points, an intermediate thymidine kinase level, i.e. a level of TK-1 above the cut-off and up to and including the value corresponding to 20 times the mean value as determined in healthy individuals values 1 point, and a high thymidine kinase level, i.e. a level of TK-1 of more than 20 times the mean value as determined in healthy individuals values 2 points.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cut-off on the protein level for TK-1 is equivalent to and includes 18 U/l in TK-1 enzymatic activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cut-off on the protein level is equivalent to and includes 18 U/Iland wherein a level of TK-1 above 18 U/l and up to and including 88 U/l values 1 point and a level of TK-1 above 88 U/l values 2 points.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the parameter age, wherein if the age is below cut-off, the value is 0 points and if the age is above cut-off, the value is 1 point in the determination of the PI.

### Claim 7 (depends on 6)

The method according to claim 6, wherein if the age is below and including 60, the value is 0 points, wherein if the age is above 60, the value is 1 point in the determination of the PI.

### Claim 8 (depends on 1)

The method according to claim 1, further comprising the parameter ECOG performance status, wherein, in case the ECOG performance status 1 or below, the value is 0 points and wherein, in case the ECOG performance status is 2 or above, the value is 1 point in the determination of the PI.

### Claim 9 (depends on 1)

The method according to claim 1, further comprising the parameter age and the parameter ECOG performance status, wherein if the age is below and including 60, the value is 0 points, wherein if the age is above 60, the value is 1 point in the determination of the PI, wherein, in case the ECOG performance status is 1 or below the value is 0 points, and wherein, in case the ECOG performance status is 2 or above, the value is 1 point in the determination of the PI.

### Claim 10 (depends on 1)

The method according to claim 1, further comprising the parameter age and the parameter ECOG performance status, wherein if the age is below and including 40, the value is 0 points, wherein if the age is above 40 and up to and including 60, the value is 1 point, wherein if the age is above 60 and up to and including 75, the value is 2 points and wherein if the age is above 75 the value is 3 points in the determination of the PI, and wherein, in case the ECOG performance status is 1 or below the value is 0 points, and wherein, in case the ECOG performance status is 2 or above, the value is 1 point in the determination of the PI.

### Claim 11

Use of a value for the level of TK-1 in the determination of a prognostic index for patients with DLBCL.

### Claim 12 (depends on 11)

The use according to claim 11, wherein the value for the level of TK-1 is combined with the other parameters as used in IPI, age adjusted IPI, R-IPI, or NCCN-IPI.

### Claim 13 (depends on 12)

The use according to claim 12 with the proviso that the value for the level of TK-1 is used to substitute the value for the level of LDH in such PI.

### Claim 14

A prognostic index (PI) for DLBCL comprising a value for the level of thymidine kinase 1.

### Claim 15 (depends on 14)

The prognostic index (PI) of claim 14, wherein said PI is selected from IPI, age adjusted IPI, R-IPI, or NCCN-IPI.
